Logo of Huzzle

Home

Matches

Explore

Manage

Summer Intern Scientist, Polymer Characterization & Formulation

image

EyePoint Pharmaceuticals

Jan 28, 2024

Applications are closed

  • Internship
    Full-time
    Starts on Jun 02
    Summer Internship
  • Science
  • Boston

Requirements

  • Passionate about drug delivery, biomaterials or biotechnology with problem solving capability
  • Comfortable working in formulation/wet lab environment
  • Have completed research or coursework in chemistry, materials science, polymers
  • Ability to work independently and in a team environment.
  • Working knowledge of Microsoft Office (Word, Excel, PowerPoint).
  • Excellent verbal and written communication, and organizational skills.
  • Basic understanding of safe working practices in a laboratory.
  • Level of Education Required:
  • Must be a student in a Bachelor’s degree program at an accredited college/university
  • Undergraduate student with a minimum of Rising
  • Preferred Field(s) of Study: Majoring in Material Science, Polymer Chemistry, Chemical Engineering, Pharmaceutical Sciences

Responsibilities

  • Polymer characterization, chemical compatibility of various bio-erodible polymers, and physicochemical testing of polymers alone and formulated products
  • Understand and/or able to quickly learn characterization techniques including techniques such as mechanical strength (Instron), Karl Fisher (KF), TGA, DSC, PXRD, Electron and Optical microscopy, and HPLC
  • Carry out formulation development activities, as required
  • Scientifically interpret complicated data sets and provide scientifically based recommendations toward successful product and formulation development.
  • Summarize data, write reports, and present in front of other team members.
image

EyePoint Pharmaceuticals

Delivering Innovation to the Eye™ NOW HIRING!

Science & Healthcare
Industry
51-200
Employees

Mission & Purpose

EyePoint Pharmaceuticals (Nasdaq: EYPT) is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert® technology for sustained intraocular drug delivery including EYP-1901, a potential six-month intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. Durasert’s proven intravitreal drug delivery platform has been safely administered to thousands of patients' eyes across four U.S. FDA-approved products, including YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, which is currently marketed by the Company. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.